Penetration into and exposure of Cefozopran (cas 113359-04-9) in pelvic retroperitoneal space exudate

Add time:08/14/2019    Source:sciencedirect.com

This study aimed to examine the penetration into and exposure of Cefozopran (cas 113359-04-9) in the pelvic retroperitoneal space exudate of patients undergoing radical hysterectomy and pelvic lymphadenectomy. Cefozopran (1 g) was administered by 1-h infusion after the end of surgery, and venous blood and exudate samples were obtained 0.5, 1, 1.5, 2, 3, 4, 5, 6, and 8 h thereafter. Drug concentrations in serum and the exudate were determined by a bioassay, analyzed pharmacokinetically, and used for a Monte Carlo simulation with minimum inhibitory concentration (MIC) data. The exudate/serum ratio of the area under the drug concentration-time curve was 0.76 ± 0.19 (mean ± SD), and the simulated concentrations were higher in the exudate than in serum after 2.4 h post-dose. The probability of attaining the pharmacodynamic exposure target (70% of the time above the MIC; i.e., probability of target attainment; PTA) was 94.9% and 100%, respectively, against Escherichia coli and Klebsiella species with 1 g every 12 h; however, 1 g every 8 h was required for a PTA value of 90% or more at an MIC of 8 μg/ml. We consider that these results will help clinicians to better understand the penetration into and exposure of cefozopran in the female genital cavity, while also helping to rationalize the dosage of this agent for gynecologicalsurgery infections.

We also recommend Trading Suppliers and Manufacturers of Cefozopran (cas 113359-04-9). Pls Click Website Link as below: cas 113359-04-9 suppliers

Prev:Original articleOn the isomerisation of Cefozopran (cas 113359-04-9) in solution
Next:Design and development of new class of Mycobacterium tuberculosis l-alanine dehydrogenase inhibitors)